Status:
COMPLETED
Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome
Lead Sponsor:
University of Giessen
Conditions:
ARDS
Hypercapnic Respiratory Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study aims to investigate the efficacy of extracorporeal CO2 removal for correction of hypercapnia in coronavirus disease 19 (COVID-19)-associated acute respiratory distress syndrome
Detailed Description
The prevalence of acute respiratory distress syndrome (ARDS) caused by COVID-19 is approximately 8%. Lung-protective ventilation is the current standard of care for ARDS. It limits lung and distal org...
Eligibility Criteria
Inclusion
- mild-to-moderate ARDS according to the Berlin definition
- lung-protective ventilation with positive end-expiratory pressure (PEEP) \> 5 cm of water on mechanical ventilation expected to last \> 24 h
- hypercapnia \<80 mmHg
- bilateral opacities on chest imaging
Exclusion
- age \< 18 years
- pregnancy
- patients with decompensated heart failure or acute coronary syndrome
- respiratory acidosis with persistent partial pressure of blood carbon dioxide (PCO2) levels \>80 mmHg
- acute brain injury
- severe liver insufficiency (Child-Pugh scores \> 7) or fulminant hepatic failure
- decision to limit therapeutic interventions
- catheter access to femoral vein or jugular vein impossible
- pneumothorax
Key Trial Info
Start Date :
May 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04351906
Start Date
May 3 2020
End Date
December 31 2024
Last Update
March 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Giessen and Marburg, Giessen
Giessen, Hesse, Germany, 35382